Cancer immunotherapy comes of age and looks for maturity
As Nature Communications celebrates a 10-year anniversary, the field has witnessed the transition of cancer immunotherapy from a pipe dream to an established powerful cancer treatment modality. Here we discuss the opportunities and challenges for the future.
Enregistré dans:
Auteurs principaux: | Amanda Finck, Saar I. Gill, Carl H. June |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b79c612e2f44404b8f5683d98f5ab4b9 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
par: Christopher Sloas, et autres
Publié: (2021) -
Single cell transcriptomics comes of age
par: Sarah Aldridge, et autres
Publié: (2020) -
Bacterial Epigenomics: Coming of Age
par: Pedro H. Oliveira
Publié: (2021) -
Euroquant at 21: “coming of age”?
par: David Unwin
Publié: (1999) -
Correction for Oliveira, “Bacterial Epigenomics: Coming of Age”
par: Pedro H. Oliveira
Publié: (2021)